Cellectis Equity Ratio

What does Cellectis do? Cellectis SA develops gene-editing based products for immuno-oncology and gene therapy, targeting specific cancer indications. The company's product portfolio includes BALLI-01 for relapsed or refractory acute lymphoblastic leukemia (r/r ALL), NatHaLi-01 for relapsed or refractory B-cell Non-Hodgkin's Lymphoma (B-NHL), ALPHA3 for Large B-Cell Lymphoma (LBCL), TRAVERSE for advanced or metastatic clear cell renal cell carcinoma (RCC), and Melanoma for unresectable or metastatic melanoma. These products are in clinical development stages, focusing on evaluating safety, expansion, persistence, and clinical activity in targeted patient populations. The company operates as a clinical stage biotechnology firm with a focus on allogeneic chimeric antigen receptor T-cell therapies and gene therapy product candidates. Cellectis SA's primary revenue stream comes from the development and potential future commercialization of its gene-editing therapies. The company is currently in the clinical stage, meaning it does not yet have commercialized products generating revenue. Instead, it relies on funding from research grants, partnerships, and equity financing to support its ongoing clinical trials and development activities. The company's focus on specific cancer types such as ALL, B-NHL, LBCL, RCC, and melanoma targets patients with unmet medical needs, positioning itself for potential future partnerships with pharmaceutical companies for further development and commercialization. The company's target segments include patients with relapsed or refractory cancers, specifically those suffering from r/r ALL, B-NHL, LBCL, RCC, and melanoma. These segments represent significant unmet medical needs in oncology, with Cellectis SA aiming to provide novel therapeutic options through its gene-editing platform. The company's development pipeline is designed to address these specific indications, with each product candidate targeting a distinct patient population requiring innovative treatments. Cellectis is one of the most popular companies on Eulerpool.